TERNS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.91 USD | +5.82% |
|
+7.68% | -24.35% |
| Apr. 10 | Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer | CI |
| Mar. 27 | UBS Trims Terns Pharmaceuticals Price Target to $18 From $19, Maintains Buy Rating | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 178.6 | 504.1 | 401 | 317.6 | - | - |
| Enterprise Value (EV) 1 | 130.9 | 360.8 | 321.1 | 112.9 | 131.2 | 44.91 |
| P/E ratio | -3.2 x | -6.1 x | -5.11 x | -3.52 x | -3.48 x | -3.86 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 179 x | - | - | 190 x | 146 x | 338 x |
| EV / Revenue | 131 x | - | - | 67.6 x | 60.4 x | 47.8 x |
| EV / EBITDA | -2.65 x | -5.86 x | -3.14 x | -1 x | -1.05 x | -0.31 x |
| EV / FCF | -3.11 x | -7.31 x | -4.76 x | -1.21 x | -1.3 x | -0.37 x |
| FCF Yield | -32.2% | -13.7% | -21% | -82.4% | -77.1% | -268% |
| Price to Book | 1.11 x | 1.32 x | 1.81 x | 1.4 x | 1.82 x | 1.76 x |
| Nbr of stocks (in thousands) | 25,267 | 49,516 | 61,795 | 64,675 | - | - |
| Reference price 2 | 7.070 | 10.18 | 6.490 | 4.910 | 4.910 | 4.910 |
| Announcement Date | 3/3/22 | 3/27/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 1 | - | - | 1.671 | 2.171 | 0.94 |
| EBITDA 1 | - | -36.63 | -49.35 | -61.54 | -102.3 | -112.7 | -124.9 | -143.5 |
| EBIT 1 | -70.2 | -37.02 | -49.86 | -62.03 | -102.6 | -114 | -129.9 | -145.5 |
| Operating Margin | - | - | -4,986% | - | - | -6,820.77% | -5,982.84% | -15,478.62% |
| Earnings before Tax (EBT) 1 | - | -39.76 | -49.65 | -59.99 | -89.97 | -109.1 | -127 | -146.5 |
| Net income 1 | - | -29.35 | -50.16 | -60.34 | -90.21 | -108.2 | -127.5 | -146.6 |
| Net margin | - | - | -5,015.8% | - | - | -6,473.33% | -5,870.84% | -15,590.74% |
| EPS 2 | -26.74 | -102.9 | -2.210 | -1.670 | -1.270 | -1.394 | -1.411 | -1.272 |
| Free Cash Flow 1 | - | -30.39 | -42.17 | -49.38 | -67.44 | -93.12 | -101.2 | -120.2 |
| FCF margin | - | - | -4,216.7% | - | - | -5,571.34% | -4,658.34% | -12,789.5% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/20 | 3/30/21 | 3/3/22 | 3/27/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | 1.95 | - |
| EBITDA 1 | -11.76 | -13.76 | -13.68 | -13.95 | -17.18 | -16.74 | -24.08 | -21.09 | -33.11 | -23.99 | -26 | -28 | -29 | -30 | - |
| EBIT 1 | -11.87 | -13.88 | -13.82 | -14.08 | -17.29 | -16.83 | -24.16 | -21.16 | -33.18 | -24.06 | -27.61 | -28.23 | -31.31 | -29.07 | -25.29 |
| Operating Margin | - | -1,387.8% | - | - | - | - | - | - | - | - | - | - | - | -1,490.67% | - |
| Earnings before Tax (EBT) 1 | -11.82 | -13.81 | -13.75 | -13.92 | -16.81 | -15.5 | -21.47 | -17.82 | -29.71 | -20.97 | -26.78 | -27.58 | -31.66 | -27.76 | - |
| Net income 1 | -11.84 | -14.25 | -13.77 | -13.93 | -16.82 | -15.82 | -21.47 | -17.9 | -29.77 | -21.02 | -26.8 | -27.58 | -31.66 | -27.78 | - |
| Net margin | - | -1,424.8% | - | - | - | - | - | - | - | - | - | - | - | -1,424.77% | - |
| EPS 2 | -0.4700 | -0.5600 | -0.5500 | -0.5500 | -0.4400 | -0.2900 | -0.3100 | -0.2500 | -0.4200 | -0.2900 | -0.3503 | -0.3537 | -0.3812 | -0.3329 | -0.3161 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/3/22 | 5/16/22 | 8/8/22 | 11/9/22 | 3/27/23 | 5/15/23 | 8/8/23 | 11/14/23 | 3/14/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 62 | 47.7 | 143 | 79.9 | 205 | 186 | 273 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -30.4 | -42.2 | -49.4 | -67.4 | -93.1 | -101 | -120 |
| ROE (net income / shareholders' equity) | - | -234% | -27.6% | -33.9% | -35.3% | -39.3% | -43.4% |
| ROA (Net income/ Total Assets) | -50.5% | -38.5% | -26.5% | -32.5% | -34% | -43.3% | -64% |
| Assets 1 | 58.1 | 130.2 | 227.5 | 277.8 | 318.5 | 294.5 | 229.1 |
| Book Value Per Share 2 | -412.0 | 6.340 | 7.690 | 3.580 | 3.500 | 2.700 | 2.790 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | 0.58 | 0.34 | 0.28 | 0.05 | 0.64 | 0.69 | 0.72 |
| Capex / Sales | - | 34% | - | - | 38.49% | 31.67% | 76.48% |
| Announcement Date | 3/30/21 | 3/3/22 | 3/27/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.91
USD
Average target price
14.21
USD
Spread / Average Target
+189.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.35% | 318M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- TERN Stock
- Financials Terns Pharmaceuticals, Inc.
